Alnylam Pharmaceuticals Inc

자세한 내용은 Alnylam Pharmaceuticals Inc 회사

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

회사 정보

종목 코드 ALNY

회사 이름Alnylam Pharmaceuticals Inc

상장일May 28, 2004

CEODr. Yvonne L. Greenstreet, M.D.

직원 수2230

유형Ordinary Share

회계 연도 종료May 28

주소675 W Kendall St

도시CAMBRIDGE

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호02142-1168

전화16175518200

웹사이트https://www.alnylam.com/

종목 코드 ALNY

상장일May 28, 2004

CEODr. Yvonne L. Greenstreet, M.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

49.35K

--

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

47.81K

+40.80%

Mr. Tolga Tanguler

Chief Commercial Officer

28.01K

+95.27%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

+3.87%

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

+21.31%

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

Ms. Carolyn R. Bertozzi, M.D.

Independent Director

775.00

--

Dr. Olivier Brandicourt, M.D.

Independent Director

775.00

--

Mr. Peter N. Kellogg

Independent Director

775.00

--

Ms. Colleen F. Reitan

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

49.35K

--

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

47.81K

+40.80%

Mr. Tolga Tanguler

Chief Commercial Officer

28.01K

+95.27%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

+3.87%

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

+21.31%

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

사업별USD

이름

수익

비율

AMVUTTRA

309.99M

52.17%

GIVLAARI

66.97M

11.27%

Other

57.56M

9.69%

Regeneron Pharmaceuticals

51.04M

8.59%

ONPATTRO

49.49M

8.33%

Other

59.15M

9.95%

지역별USD

이름

수익

비율

United States

271.44M

45.68%

Europe

146.16M

24.60%

Net revenues from collaborations

99.19M

16.69%

Rest of World

50.94M

8.57%

Royalty revenue

26.47M

4.45%

사업별

지역별

사업별USD

이름

수익

비율

AMVUTTRA

309.99M

52.17%

GIVLAARI

66.97M

11.27%

Other

57.56M

9.69%

Regeneron Pharmaceuticals

51.04M

8.59%

ONPATTRO

49.49M

8.33%

Other

59.15M

9.95%

주식 보유 통계

마지막 업데이트: Thu, Aug 7

주주

주주 유형

주주

비율

Capital World Investors

12.78%

Fidelity Management & Research Company LLC

11.16%

The Vanguard Group, Inc.

10.10%

Capital Research Global Investors

5.46%

BlackRock Institutional Trust Company, N.A.

5.14%

Other

55.37%

주주

비율

Capital World Investors

12.78%

Fidelity Management & Research Company LLC

11.16%

The Vanguard Group, Inc.

10.10%

Capital Research Global Investors

5.46%

BlackRock Institutional Trust Company, N.A.

5.14%

Other

55.37%

주주 유형

주주

비율

Investment Advisor

66.39%

Investment Advisor/Hedge Fund

20.85%

Corporation

3.39%

Hedge Fund

3.12%

Sovereign Wealth Fund

1.97%

Research Firm

1.56%

Pension Fund

1.25%

Bank and Trust

1.10%

Individual Investor

0.40%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

1300

131.78M

100.54%

-3.28M

2025Q1

1315

132.55M

101.67%

-2.42M

2024Q4

1263

130.73M

100.99%

-1.47M

2024Q3

1225

126.90M

98.51%

-1.26M

2024Q2

1183

123.30M

96.32%

+1.12M

2024Q1

1172

117.88M

93.23%

-5.46M

2023Q4

1169

120.70M

96.18%

-5.54M

2023Q3

1125

121.55M

96.89%

-6.15M

2023Q2

1119

122.11M

98.30%

-6.32M

2023Q1

1116

123.13M

99.37%

-5.56M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Capital World Investors

16.75M

12.85%

+149.10K

+0.90%

Mar 31, 2025

Fidelity Management & Research Company LLC

14.62M

11.22%

+1.68M

+13.00%

Mar 31, 2025

The Vanguard Group, Inc.

13.00M

9.97%

+322.72K

+2.55%

Mar 31, 2025

Capital Research Global Investors

7.15M

5.49%

+186.22K

+2.67%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.73M

5.16%

-22.21K

-0.33%

Mar 31, 2025

Regeneron Pharmaceuticals Inc

4.44M

3.41%

--

Mar 31, 2025

T. Rowe Price Investment Management, Inc.

4.42M

3.39%

+33.70K

+0.77%

Mar 31, 2025

T. Rowe Price Associates, Inc.

3.41M

2.61%

+178.26K

+5.52%

Mar 31, 2025

State Street Global Advisors (US)

3.37M

2.58%

-56.29K

-1.64%

Mar 31, 2025

Dodge & Cox

3.35M

2.57%

-188.50K

-5.32%

Mar 31, 2025

430.940USD

Alnylam Pharmaceuticals Inc

430.940

개요

회사

금융